We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Acadia Pharmaceuticals Inc | NASDAQ:ACAD | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 17.05 | 16.40 | 17.75 | 0 | 09:00:08 |
On February 26, 2015, ACADIA announced its 2014 fourth quarter and year-end financial results and told investors that it "remained on track to submit its New Drug Application (NDA) to the Federal Drug Administration (FDA) in the first quarter of 2015." Shortly thereafter, on March 11, 2015, ACADIA issued a press release announcing a change in the timing of its planned NDA submission to the FDA for its drug NUPLAZID from the first quarter of 2015 to the second half of 2015. In a separate press release the same day, ACADIA announced the retirement of the Company's Chief Executive Officer and President, Uli Hacksell.
This news and resignation announcement shocked investors, leading to a material decline in the price of ACADIA common stock. On March 12, 2015, the shares of ACADIA closed at $34.82, a decline of $7.94 per share, a precipitous drop of 22.8%.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has over 70 attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein Adler Freeman & Herz LLP by telephone at (800) 575-0735, via e-mail at classmember@whafh.com, or visit our website at www.whafh.com. All e-mail correspondence should make reference to the "ACADIA investigation."
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
CONTACT: Wolf Haldenstein Adler Freeman & Herz LLP Gregory Stone, Director of Case and Financial Analysis Email: gstone@whafh.com or classmember@whafh.com Tel: (800) 575-0735 or (212) 545-4774
1 Year Acadia Pharmaceuticals Chart |
1 Month Acadia Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions